PTGX
Protagonist Therapeutics Inc
141.90$
+3.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 96.0% | 95.7% | 88.6% | 92.2% | 98.6% | 93.8% | 97.3% | 98.0% | 98.0% | 99.3% | 79.4% | 86.2% | |
| 90.3% | 27.3% | 22.4% | 64.8% | 59.0% | 21.3% | 36.2% | 35.6% | 50.7% | 52.2% | 13.1% | 19.2% | |
| 90.3% | 80.3% | 82.6% | 87.9% | 92.4% | 85.9% | 94.2% | 94.0% | 95.7% | 95.4% | 56.3% | 84.7% | |
| 5.1% | 4.8% | 2.4% | 1.1% | 3.3% | 4.4% | 1.2% | 1.5% | 0.0% | 2.9% | 22.6% | 0.7% | |
| 0.1% | 8.5% | -8.1% | -5.3% | 1.5% | 3.1% | 1.2% | 2.4% | 0.0% | -2.9% | – | – | |
| 4.0% | 4.1% | 0.6% | 0.5% | 0.6% | 5.0% | 0.5% | 1.9% | 0.6% | – | – | – | |
| – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 23.0% | 35.4% | 6.8% | 26.3% | 19.3% | 48.4% | 13.8% | 13.7% | 13.0% | 5.9% | 9.3% | 8.2% | |
| 13.1% | 21.1% | 6.8% | 26.0% | 18.8% | 22.9% | 12.4% | 12.7% | 12.6% | 5.9% | 6.4% | 6.8% | |
| – | – | – | – | 0.8% | 0.8% | 0.4% | 0.6% | 1.0% | 0.3% | 0.1% | 0.3% | |
| 3.4% | 8.4% | 1.2% | 0.8% | 4.1% | 1.8% | 0.9% | 0.5% | 1.5% | 0.2% | 0.2% | 0.8% | |
| – | 14.3% | 0.0% | 0.0% | – | 6.3% | – | – | – | – | – | – | |
| 77.0% | 64.6% | -68.7% | -62.0% | -100.7% | 51.6% | 86.2% | 86.3% | 87.0% | 94.1% | 90.7% | 91.8% | |
| -121.6% | -184.7% | -68.7% | -62.0% | -100.7% | -140.5% | -87.5% | -117.7% | -216.5% | -172.0% | -45.7% | -70.3% | |
| 57.0% | 39.6% | 6.9% | 10.8% | 16.0% | 16.7% | 10.6% | 13.3% | 19.8% | 15.9% | 8.7% | 9.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.